• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    International Stem Cell Moves Forward with Traumatic Brain Injury Phase II Clinical Trial

    Bryan Mc Govern
    Sep. 20, 2017 09:52AM PST
    Genetics Investing

    International Stem Cell announced the completion of its preclinical studies in Traumatic Brain Injury program will position it to commence a Phase II clinical trial in Australia.

    International Stem Cell (OTCQB:ISCO) announced the completion of its preclinical studies in Traumatic Brain Injury program will position it to commence a Phase II clinical trial in Australia.
    As quoted in the press release:

    “Often referred to as a silent epidemic, TBI represents a significant unmet medical need with millions affected annually. Based on the results of our proprietary ISC-hpNSC® demonstrated in our Parkinson’s disease clinical trial and in the preclinical studies conducted by the world-renowned academic collaborator, we believe ISC-hpNSC® can be an effective therapy for TBI” remarked Andrey Semechkin, PhD., Co-Chairman and CEO of ISCO.
    “We are very impressed by the results of our TBI preclinical studies. Both motor and cognitive functions improved with neural stem cells ISC-hpNSC® transplantation without any safety issues,” commented Russell Kern, PhD., Executive Vice President and Chief Scientific Officer of ISCO.

    Click here to read the full press release.

    Source: globenewswire.com

    traumatic brain injurystem cellschief scientific officeraustralia
    The Conversation (0)

    Go Deeper

    AI Powered
    Lab worker putting samples on microscope.

    Top 4 Small-cap ASX Biotech Stocks of 2025

    Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

    Hemostemix Files for Ethics Approval of its Study of Vascular Dementia

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Genetics Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES